title: Rasagiline. Teva Pharmaceutical.
abstract: Rasagiline is a selective and potent irreversible MAO(B) inhibitor which is under development by Teva for the treatment of neurological diseases. Rasagiline is in phase III trials in the US, Canada and Europe for Parkinson's disease (PD) and has completed phase II trials in Israel and Hungary. Teva planned to submit a filing in 2002 and expected to launch rasagiline in 2003. Lundbeck acquired European development and commercialization rights to rasagiline in November 1999 and, in September 2001, the company reported that it planned to file an NDA in 2003. In March 2002, analysts at Morgan Stanley Dean Witter predicted that H Lundbeck would make sales of rasagiline of DKr 100 million in 2003, rising to DKr 300 million in 2008. In the same month, launch was predicted in 2004/2005 for the PD indication, and 2005/2006 for the AD indication, by analysts at Deutsche Banc Alex Brown.
authors.affiliation: Department of Neurology, Charite-Virchow, Berlin, Germany. andreas.kupsch@charite.de
authors.forename: Andreas
authors.initials: A
authors.lastname: Kupsch
mesh_terms: D000284:Administration, Oral; D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy; D013329:Structure-Activity Relationship
chemical_list: D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; C031967:rasagiline